Albireo to participate in Cowen and HC Wainwright Global

0


BOSTON, Feb.23, 2021 (GLOBE NEWSWIRE) – Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced its participation in the upcoming 41st Cowen Annual Health Care Conference March 1-4, 2021. Ron Cooper, President and CEO of Albireo, will attend the Panel on new drug launches Wednesday, March 3, 2021 at 10:20 a.m. ET. Members of the management team will also be holding investor meetings on March 2.

The Company will also be attending the HC Wainwright Global Life Sciences Conference March 9-10, 2021. Simon Harford, Chief Financial Officer, and Pamela Stephenson, Chief Commercial Officer, will take part in a fireside chat on March 9 at 7:00 a.m. ET, which will be available on demand on the Albireo Media & Investors page ir.albireopharma.com. Ron Cooper and members of the executive team will also be holding investor meetings on March 9.

About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver disease. Albireo’s lead product candidate, odevixibat, is under development to treat rare pediatric cholestatic liver disease with pivotal Phase 3 trials in PFICs, Alagille syndrome and biliary atresia. The company has completed studies enabling IND for the new preclinical candidate A3907 and plans to advance the development of liver disease in adults. Albireo was separated from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. the Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second year in a row. For more information on Albireo, please visit www.albireopharma.com.

Media and investor contacts:
Colleen Alabiso, 857-356-3905, [email protected]
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578



Source link

Leave A Reply

Your email address will not be published.